Table of Contents – The MedTech Strategist, Vol. 4, No. 6, April 20, 2017 (48 Pages):
- Neurovascular—“Stryker Neurovascular—Has the Decade of the Brain Arrived?” by David Cassak
- Aesthetics Market—“Strong Growth and Cash-Pay Make Aesthetics an Attractive Target,” by Mary Thompson
- Precision Medicine—“How the Device Industry Can Win in Cancer Immunotherapy: Devices as Immunoadjuvants,” by Wendy Diller
- Executive Interview—“Navigating Different Junctures of Fundraising: A Conversation with John McDonough, CEO of T2 Biosystems,” by Mark Speers, Contributor
- Start-Ups To Watch—“EchoPixel: Virtual Reality Allows Surgeons to Plan More Accurate, Safer, and Shorter Surgeries,” by Mary Stuart
Stryker Neurovascular—Has the Decade of the Brain Arrived?
By David Cassak
Two decades ago, Boston Scientific pioneered the field of interventional neurovascular devices, hoping to create a complement to its successful interventional cardiology business. But the so-called “Decade of the Brain” never really materialized to the extent hoped and BSC’s financial troubles following its Guidant acquisition led the company to sell the business. The buyer: Stryker Corp. Now with an ischemic stroke technology that is producing compelling clinical results, company executives are hoping the stroke market’s long-anticipated success is finally coming.
Boston Scientific Corp.—Medtronic plc—Stryker Corp.
Strong Growth and Cash-Pay Make Aesthetics an Attractive Target
By Mary Thompson
The aesthetics industry is booming and demand for nonsurgical procedures, in particular, is soaring. One of the fastest growing new segments in the nonsurgical aesthetics space is body contouring, a market that is so promising, it was the major impetus behind two major acquisition deals this year.
Allergan plc—BTL—Cutera Inc.—Cynosure Inc.—Cytrellis Biosystems Inc.—Erchonia Corp.—Fosun Pharma—Galderma Laboratories—Hologic Inc.—Lumenis—Merz Aesthetics—MyoScience—Solta Medical—Syneron Medical Ltd.—Valeant Pharmaceuticals—Venus Concept Inc.—Zeltiq
How the Device Industry Can Win in Cancer Immunotherapy: Devices as Immunoadjuvants
By Wendy Diller
Immunotherapy has become a cornerstone of cancer treatment, presenting the opportunity of a lifetime for the biopharma industry, but until now, devices have played a minimal role in its success. Recent scientific advances have led to a belief, however, that devices can boost the efficacy of immuno-oncology drugs by priming the immune response and/or enhancing the abscopal effect in metastatic disease. This work is too new to put into financial terms, and is not likely to translate into the same level of rewards as it has for pharma, but it shows enormous promise.
BTG plc—Insightec Ltd.—Janssen Biotech—Johnson & Johnson—Varian Medical Systems
Navigating Different Junctures of Fundraising: A Conversation with John McDonough, CEO of T2 Biosystems
By Mark Speers, Contributor
At the recent MassMEDIC MedTech Investors Conference, Mark Speers, Co-Founder and Managing Director of Health Advances, interviewed John McDonough, CEO of medical diagnostics company T2 Biosystems, on the topic of capital fundraising.
T2 Biosystems Inc.
Start-Ups To Watch
EchoPixel: Virtual Reality Allows Surgeons to Plan More Accurate, Safer, and Shorter Surgeries
By Mary Stuart
Despite advances in imaging acquisition technologies, surgeons and other clinicians still work with 2D images to understand complex 3D anatomy, and that involves a kind of mental translation that makes their jobs difficult. Software company EchoPixel is extracting more information from image data acquired by conventional CT and MRI systems to create and display detailed 3D images that surgeons can use to more accurately plan surgeries. New applications keep finding the company, which has already demonstrated the benefits of its system in the repair of congenital heart defects, neurovascular treatments of brain aneurysms, virtual colonoscopy, and assuring that the products of 3D printing fit the bill.
Bioflight VR—EchoPixel Inc.—GE Healthcare—MediVis Inc.—Osso VR—Royal Philips